

National Health (Weighted average disclosed price – second transitional disclosure cycle) Amendment Determination 2012

Instrument number PB 7 of 2012

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the *National Health Act 1953*.

Dated 20 March 2012

FELICITY McNEILL

First Assistant Secretary Pharmaceutical Benefits Division Department of Health and Ageing

1 Name of Determination

- (1) This Determination is the *National Health (Weighted average disclosed price second transitional disclosure cycle) Amendment Determination 2012.*
- (2) This Determination may also be cited as PB 7 of 2012.

2 Commencement

This Determination commences on the day after it is registered.

3 Amendments to PB 82 of 2011

Schedule 1 amends the *National Health (Weighted average disclosed price – second transitional disclosure cycle) Determination 2011* (PB 82 of 2011).

Schedule 1 Amendments

[1] Schedule 1, After

76	Gemcitabine	Solution concentrate for I.V.	Injection	Gemcitabine Ebewe	30.41	32.70
		infusion 500 mg (as				
		hydrochloride) in 50 mL				

insert:

3

76A	Gemcitabine	Solution concentrate for I.V. infusion 1g (as hydrochloride) in 25 mL	Injection	Gemcitabine Ebewe	60.81	65.38
76B	Gemcitabine	Solution concentrate for I.V. infusion 2 g (as hydrochloride) in 50 mL	Injection	Gemcitabine Ebewe	121.90	131.07
76C	Gemcitabine	Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 5 mL	Injection	Gemcitabine Ebewe	12.31	13.24
76D	Gemcitabine	Solution for injection 1 g (as hydrochloride) in 26.3 mL	Injection	DBL Gemcitabine Injection	60.81	65.38
76E	Gemcitabine	Solution for injection 2 g (as hydrochloride) in 52.6 mL	Injection	DBL Gemcitabine Injection	121.90	131.07
76F	Gemcitabine	Solution for injection 200 mg (as hydrochloride) in 5.3 mL	Injection	DBL Gemcitabine Injection	12.31	13.24

[2] Schedule 1, After

96	Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in	Injection	Irinotecan Actavis 500	194.45	209.07
		25 mL				

insert:

ſ	96A	Irinotecan	I.V. injection containing irinotecan	Injection	Tecan	194.45	209.07
	00/1	miotodan	hydrochloride trihydrate 500 mg in	injoonon		10 11 10	200.01
			25 mL				

Note

4

1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act* 2003. See http://www.frli.gov.au.